|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 4
Zeitschriftenartikel
Jacob, Anne Sophie; Kaul, Helen; Fuchs, Michael; Gillessen, Sarah; Kreissl, Stefanie; Pluetschow, Annette; Momotow, Jesko; Schaub, Valdete; Huettmann, Andreas; Haenel, Mathias; Zimmermann, Andreas; Dierlamm, Judith; Meissner, Julia; Mathas, Stephan; Martin, Sonja; Engert, Andreas; Hallek, Michael; Borchmann, Peter und Lehmann, Clara
(2022):
Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma.
In: Infection, Bd. 50, Nr. 4: S. 925-932
Kreissl, Stefanie; Goergen, Helen; Buehnen, Ina; Kobe, Carsten; Moccia, Alden; Greil, Richard; Eichenauer, Dennis A.; Zijlstr, Josee M.; Markova, Jana; Meissner, Julia; Feuring-Buske, Michaela; Soekler, Martin; Beck, Hans Joachim; Willenbacher, Wolfgang; Ludwig, Wol-Dieter; Pabst, Thomas; Topp, Max S.; Hitz, Felicitas; Bentz, Martin; Keller, Ulrich Bernd; Kuehnhardt, Dagmar; Ostermann, Helmut; Hertenstein, Bernd; Ulitzky, Wafter A.; Maschmeyer, Georg; Vieler, Tons; Eich, Hans; Baues, Christian; Stein, Harald; Fuchs, Michael; Diehl, Volker; Dietlein, Markus; Engert, Andreas und Borchmann, Peter
(2021):
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.
In: Lancet Haematology, Bd. 8, Nr. 6, E398-E409
Borchmann, Peter; Haverkamp, Heinz; Lohri, Andreas; Mey, Ulrich; Kreissl, Stefanie; Greil, Richard; Markova, Jana; Feuring-Buske, Michaela; Meissner, Julia; Duehrsen, Ulrich; Ostermann, Helmut; Keller, Ulrich; Maschmeyer, Georg; Kuhnert, Georg; Dietlein, Markus; Kobe, Carsten; Eich, Hans; Baues, Christian; Stein, Harald; Fuchs, Michael; Diehl, Volker und Engert, Andreas
(2017):
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP(escalated) alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.
In: Lancet Oncology, Bd. 18, Nr. 4: S. 454-463
Eichenauer, Dennis A.; Plütschow, Annette; Kreissl, Stefanie; Sökler, Martin; Hellmuth, Johannes C.; Meissner, Julia; Mathas, Stephan; Topp, Max S.; Behringer, Karolin; Klapper, Wolfram; Kuhnert, Georg; Dietlein, Markus; Kobe, Carsten; Fuchs, Michael; Diehl, Volker; Engert, Andreas und Borchmann, Peter
(2017):
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
In: Lancet Oncology, Bd. 18, Nr. 12: S. 1680-1687